Cairn Biosciences

Executive Summary

Cairn Biosciences is a preclinical-stage biotechnology company leveraging its proprietary COMPASS platform to discover novel therapeutics in oncology and cell therapy. By mapping multiscale cell dynamics, COMPASS enables the identification of previously inaccessible targets and drug candidates from complex disease biology. Founded in 2018 and headquartered in San Francisco, the company focuses on unlocking new mechanisms of action that address high unmet needs in cancer. Its approach aims to overcome the limitations of traditional drug discovery by integrating dynamic cellular data to reveal disease-driving pathways. Though still in early development, Cairn's platform has the potential to generate a pipeline of first-in-class therapies targeting difficult-to-drug targets, particularly in immuno-oncology and cell therapy. The company is privately held and has not disclosed funding rounds or valuation, indicating a lean operational model focused on platform validation and preclinical advancement.

Upcoming Catalysts (preview)

• Q1 2027Preclinical proof-of-concept data for lead program60% success
• Q3 2027Completion of IND-enabling studies40% success
• Q2 2027Strategic partnership or licensing deal30% success